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ABSTRACT 
Identification of novel protein interactions and their mediators is fundamental in understanding 
cellular processes and is necessary for protein-targeted therapy. Evidently high throughput formatting 
of these applications in living cells would be beneficial, however no adequate system exists. We present a 
novel platform technology for the high throughput screening and verification of protein interactions in 
living cells. The platform’s series of Dual Expression Recombinase Based (DERB) destiny vectors 
individually encode two sets of recombinase recognizable sequences for inserting the protein open 
reading frame (ORF) of interest, two sets of promoters and reporter tags in frame with the ORFs for 
detecting interactions. Introduction into living cells (prokaryotic and eukaryotic) enables the detection 
of protein interactions by fluorescence resonance energy transfer (FRET) or bimolecular fluorescence 
complementation (BiFC). The DERB platform shows advantages over current commercialized systems 
by DERB vectors validated through proof-of-principle experiments and the identification of an 
unknown interaction. 
  
 
INTRODUCTION 
The completion of the human genome sequencing project has presented the opportunity and challenge of 
identifying a staggering number of gene products, proteins, their interactions and modifiers. In addition to the 
35,000 predicted proteins in the human genome, mutation and alternative splicing contribute further to this 
astounding number and to the quantity of possible cellular interactions1. Accordingly, the targeted therapy of a 
single protein can affect processes outside of the original intent which would be avoided with the introduction 
of a large-scale pre-screening system to identify interaction partners. The integration of a technical 
development into protein therapy will provide significant improvements to current research methods and aid 
in the prevention and treatment of disease2,3.  
The most familiar method for screening protein interactions in/ex vivo is the yeast two-hybrid assay. It is 
prevalent despite its complicated, time consuming protocol and requirement for the results to be confirmed in 
additional living cell systems4. Alternative in/ex vivo approaches include FRET5-7 and BiFC8,9, however the 
plasmids for analysis require individual construction which reduces the screening efficiency5-10. Integration of 
these approaches into efficient high throughput detection has thus far not been successful. 
In order to overcome these limitations, we have developed a platform that supports high throughput screening 
and verification of protein interactions in living cells. We have engineered a DERB (Dual Expression 
Recombinase Based) vector platform to facilitate highly efficient cloning/subcloning of potential interaction 
partners into a final expression vector. The DERB vectors encode the sequences of two separate sets of 
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promoters, reporter tags for FRET or BiFC detection, and recombinase recognizable sites for the insertion of 
ORF of the proteins of interest and selection securities for efficient cloning. Introducing a protein couplet into 
a single destiny vector through two-step recombination eliminates the requirements of multiple step 
restriction-purification-ligation subcloning and co-transfection. Additionally, introducing the vectors into 
living cells, both prokaryotic and eukaryotic, enables the examination of the proteins of interest utilizing 
generic laboratory equipment including but not limited to the plate reader, flow cytometer, fluorescent 
microscope and/or confocal microscope. 
      To appreciate the potential of the DERB platform and demonstrate its relevance in hypothesis-driven 
research we applied it to detect protein interactions in the adiponectin signaling pathway. This signal 
transduction pathway consisting of recently identified receptors and down stream constituents is becoming an 
important area of research and development due to its role in public health issues including diabetes 
mellitus11, obesity and cancer12,13. However, limited knowledge of the adiponectin receptor interaction 
partners restricts the development of therapeutic reagents for relief from the associated diseases. The 
identification of a novel receptor interaction in the pathway is attributed to the DERB technology.  The 
potential of this method extends to include the automated ex vivo screening of therapeutics to modulate 
essential interactions, such as the adiponectin receptor interaction identified. The platform ultimately supplies 
an innovative method for the screening and confirmation of protein interactions in living cells, which can be 
effectively integrated into a high throughput configuration facilitating the process of screening for modulators 
that regulate protein-protein interactions. 
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RESULTS 
Efficient integration of desired protein ORFs 
The proteins of interest present in individual donor vectors were sequentially introduced into the recombinase 
recognizable loci of a DERB destiny vector (Fig. 1ai). Two independent recombination reactions brought the 
destiny vector to its dual protein expression vector formation and enabled protein interaction detection through 
FRET or BiFC after introducing into the cells. The initial LR Clonase recombination integrated ORF1 
between the Att sites of the destiny vector while the subsequent CRE recombinase recombination inserted 
ORF2 into the LoxP site. The LR Clonase mediated reaction product was introduced into Escherichia coli (E. 
coli) DH5α for negative selection of the recombination byproduct and unsuccessful insertion constructs. The 
ccdB gene was either introduced into the reaction byproduct plasmid, devoid of ORF1, or remained in the 
destiny vector and prevented growth of both plasmids in DH5α. Confirmation of the Att recombination with 
ORF1 was achieved through polymerase chain reaction (PCR) with primers specific to the ORF1 sequence 
and Att insert boundary (Fig. 1aii). The subsequent reaction mixture of the CRE recombination was directly 
transformed into E. coli DH5α whereby successful insertions manifested in large concentric clones and 
unsuccessful clones succumbed to chloramphenicol and sucrose. Examination of the putative dual expression 
clones with electrophoresis identified effective ORF2 introductions evident by the increased plasmid size, 
proportional to the length of insertion, attained above the size without insertion (Fig. 1aiii). Collectively the 
SucB and antibiotic selection securities prevented the growth of clones with unsuccessful recombination 
vectors and provided the foundation of the platform’s cloning efficiency (Supplementary DERB Selection 
Strategy). Finalized dual expression vectors were introduced into prokaryotic (E. coli BL21(DE3)) or 
eukaryotic (HeLa) cells dependent upon the specified promoter of the destiny vector utilized. Induction of the 
system translated the two proteins individually fused to either the Yc Yn (Fig. 1bi) or ECFP EYFP (Fig. 1bii) 
set of tags for BiFC or FRET protein interaction detection, respectively.  
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Figure 1 | Schematic of the two recombination reactions between two donor vectors and DERB destiny vector 
generating a dual expression vector for immediate protein-protein interaction detection. (a)(i) Insertion of the ORFs 1 
and 2 of interest from donor vectors with Att and LoxP loci respectively into a destiny vector designated by its promoter 
presence and interaction detection (BiFC or FRET). (ii) ORF1 introduction into a T7 and FRET destiny vector was 
mediated with LR Clonase. PCR confirmed the successful single expression vectors by forward primer, specific to the 
ORF1 sequence, and reverse primer, binding specific to the Att insert boundary, to permit fragment amplification. 
Insertion was successful in clones present in lanes 2-13 which contrasted the no clonase, no insertion negative control 
vector in lane 14. (iii) Successful insertions performed ORF2 introduction from the LoxP donor vector with CRE 
recombinase. Electrophoresis examination of the plasmid isolated from picked clones revealed successful ORF2 
presence in lanes 3-9 and 11-13 by the evident 3kb size increase above the no recombinase control in lane 2and 10 
without insertion. Methodology of the platform construction is presented in Supplementary Methods 1. (b) Dual 
expression vectors were introduced into the desired cell model and induced to express the proteins of interest (ORF1 
and ORF2) fused to the (i) Yc Yn or (ii) ECFP EYFP set of reporter tags. Positive interaction partners reconstituted 
fluorescence through BiFC or generated FRET whereas non-interacting proteins did not generate a signal.  
 
 
Innate ability for protein interaction detection 
Standardized expression vector controls were developed for validation of FRET and BiFC results in all destiny 
vector derivative lineages. The p-ECFPEYFP expression type vectors expressed the ECFPEYFP fusion 
protein and demonstrated a positive FRET signal. Conversely to the fusion, ECFP and EYFP or Yc and Yn 
were individually expressed from the p-ECFP-EYFP or p-Yc-Yn derivatives and demonstrated a negative 
interaction. The reported interaction partners of APPL1-ADIPOR1, APPL1-ADIPOR211 and homopolymer 
VIM were additionally integrated into a FRET and BiFC positive control collection while VIM and TUBA1B 
contributed to the negative interaction controls. Vimentin is well known to form polymers while there is no 
direct interaction between vimentin and tubulin structure14. Consideration of the differences in post-
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translational modification between prokaryotic and eukaryotic cells prompted twin line analysis of the 
platform and was mediated through the derivatives and associated controls aforementioned. Plate reader 
examination established a p-ECFP-EYFP background fluorescence level below the p-ECFPEYFP fusion 
FRET intensity (FRETN). Constructs p-ECFPAPPL1-EYFPADIPOR1 and p-ECFPAPPL1-EYFPADIPOR2 
displayed positive interaction FRETN mirroring the fusion value (Fig. 2a). Ultimately every control in the 
system whether expressed in a prokaryotic or eukaryotic line attained parallel FRETN behavior, enabling 
examination in either cell line. Confocal microscope examination of pFer-ECFPAPPL1-EYFPADIPOR1 and 
pFer-ECFPAPPL1-EYFPADIPOR2 further validated results (Fig. 2b). 
 
 
Figure 2 | FRET detection of protein interactions validated with the use of both plate reader and confocal microscope 
analysis (a) The 96-well formatted plate reader detected similar FRETN from protein couplets encoded in both 
prokaryotic (pT7) and eukaryotic (pFer) DERB vector derivatives. Unspecific p-ECFP-EYFP established background 
was surpassed by the p-ECFPEYFP fusion in the prokaryotic (p=0.0014) and eukaryotic (p=0.0005) cells. The APPL1 
and ADIPOR1 in E. coli (p=0.011) and HeLa cells (p=0.0005) as well as the pT7-ECFPAPPL1-EYFPADIPOR2 
(p=0.003) and pFer-ECFPAPPL1-EYFPADIPOR2 (p=0.00005) FRETN values all constituted positive interaction. (b) 
Confocal visualization of eukaryotic (HeLa) cells of ECFP (top row), EYFP (middle row) and FRET (bottom row) 
fluorescence distribution ensured dual protein presence. The pFer-ECFPAPPL1-EYFPADIPOR1 and pFer-
ECFPAPPL1-EYFPADIPOR2 transfected cells surpassed the background FRETN fluorescence validating interaction 
detection.   
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BiFC protein interaction detection 
An alternative destiny vector lineage was engineered to integrate two proteins of interest through the 
aforementioned two-step recombination and translate the proteins fused to divisions of EYFP. The C-terminal 
(Yc) and N-terminal (Yn) parts generated no fluorescence individually however fluoresced when brought into 
close proximity of each other, and thus its fusion with interacting proteins generated fluorescence8,9. HeLa 
cells were transfected with BiFC dual expression vectors and screened for EYFP fluorescence with both the 
96-well plate reader and flow cytometer while fluorescent microscope analysis provided visual validation of 
the interactions. Expression vector pFer-YcVIM-YnVIM transfected cells generated substantial EYFP 
emission above the negligible pFer-YcVIM-YnTUBA1B background in all analyzers. The plate reader 
confirmed previous FRET results by detecting positive interactions in cells expressing APPL1 with ADIPOR1 
or ADIPOR2 (data not shown). Flow cytometry further validated positive interactions by detecting EYFP 
fluorescent cell populations in pFer-YcAPPL1-YnADIPOR1 transfected HeLa cells (Fig. 3a). Consecutive 
confirmation with fluorescent microscopy demonstrated interactions among pFer-YcVIM-YnVIM, pFer-
YcAPPL1-YnADIPOR1 protein partners (Fig. 3b). 
 
 
Figure 3 | Protein interactions detected in the DERB platform with BiFC were validated by flow cytometer (top) and 
fluorescent microscope (bottom) analysis. (a) The absence of EYFP fluorescence was in (i) pFer-YcVIM-YnTUBA1B 
whereas positive cell populations were prominent with (ii) pFer-YcVIM-YnVIM and (iii) pFer-YcAPPL1-YnADIPOR1. (b) 
The fluorescent microscope background level was established with the (i) pFer-YcVIM-YnTUBA1B and was surpassed 
by (ii) pFer-YcVIM-YnVIM and (iii) pFer-YcAPPL1-YnADIPOR1 transfected HeLa cells.  
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Protein interaction analysis validated with immunoprecipitation 
Destiny vector pFer-ECFPAPPL1-EYFPADIPOR1 HeLa cell lysate was incubated with anti-ADIPOR1 
followed by protein G beads to form bead- anti-ADIPOR1-ADIPOR1 complexes. Collection of the complexes 
and proteins associated to ADIPOR1 were western blotted with anti-APPL1 and HRP conjugated secondary 
antibody. Bands revealed APPL1 presence within the ADIPOR1 collection and confirmed interaction (Fig. 4). 
 
 
Figure 4 | Immunoprecipitation confirmed DERB platform protein interaction analysis. (a) APPL1 presence in the pFer-
ECFPAPPL1-EYFPADIPOR1 transfected HeLa cell lysate was identified prior (-) to and following (+) 
immunoprecipitation of ADIPOR1. (b) Anti-actin control identified the presence of actin prior (-) to but not following (+) 
immunoprecipitation of identical ADIPOR1 complexes confirming the APPL1 and ADIPOR1 protein interaction. 
 
 
Novel interaction attributed to DERB platform 
Consistent validation of the DERB platform with standardized controls prompted investigation beyond known 
interacting partners. Standardized control derivatives pECFP-EYFP, p-ECFPVIM-EYFPTUBA1B, p-YcVIM-
YnTUBA1B, p-ECFPEYFP, p-ECFPVIM-EYFPVIM and p-YcVIM-YnVIM established result consistency 
throughout the various applications. FRET investigation with pT7-ECFPADIPOR1-EYFPADIPOR1 resulted in 
the identification of a novel receptor interaction (Fig. 5a). Investigation of pFer-YcADIPOR1-YnADIPOR1 
with a 96-well plate reader and flow cytometer confirmed results identified with the FRET prokaryotic 
construct (Fig. 5b). Further affirmation of the protein interaction through fluorescent microscopy with the pFer-
YcADIPOR1-YnADIPOR1 expression vector supported all previous results. Validity was furthered through the 
western blotting of the pFer-YcADIPOR1-YnADIPOR1 construct which revealed unbiased detection and the 
conclusion of the ADIPOR1- ADIPOR1interaction (Fig. 5c).  
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Figure 5 | DERB platform verification of a novel protein interaction between ADIPOR1 and ADIPOR1. (a) Prokaryotic 
construct pT7-ECFPADIPOR1-EYFPADIPOR1 transformed into E. coli BL21(DE3) exhibited substantial FRETN above 
pT7-ECFP-EYFP and pT7-ECFPVIM-EYFPTUBA1B. (b) BiFC in eukaryotic (HeLa) cells utilized (i) pFer-ECFPVIM-
EYFPTUBA1B presented no obvious fluorescence in the flow cytometer analysis (top) and no fluorescence was 
visualized with the fluorescent microscope (bottom). (ii) pFer-YcADIPOR1-YnADIPOR1 showed a positive EYFP 
population (top) and obvious reconstitution of EYFP under the microscope (bottom) thus supporting the putative 
ADIPOR1-ADIPOR1 interaction. (c) Western blotting showed HeLa cells transfected with pFer-YcADIPOR1-
YnADIPOR1 expressed YcADIPOR1 and YnADIPOR1 proteins with expected sizes 52.7 and 61.6 kDa respectively. 
Differential sizes of an identical ORF was attributed to the unequal division of the fused Yc and Yn parts and enabled 
western blot quantification of the proteins. (i) Substantial band intensity was presented after development with anti-
EGFP polyclonal antibody (cross-reacted with EYFP) and exposed comparable protein levels for interaction detection. 
(ii) Mock transfected HeLa cell lysate was negative for the presence of Yc or Yn and revealed antibody specificity. 
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DISCUSSION  
 
Modern research in the field of protein interactions in living cells is restricted in practice by the limited 
number of known proteins and/or interaction partners15-17. Consequently, there is an emerging demand for the 
high throughput screening (HTS) of protein interactions and modifiers to ultimately benefit the development 
of protein-based therapeutics with minimal side effects18. HTS integration of this procedure into living cells is 
dependent upon the degree of automation at two fundamental stages; the cloning/subcloning of protein ORFs 
and detection of protein interactions.  
Our DERB platform provides an efficient subcloning approach for the HTS and verification of novel protein 
interactions with its ORF contained donor vectors and line of dual-expression destiny vectors. Companies 
including Open Biosystems, Clontech and Invitrogen offer donor vector libraries with various protein ORFs 
that are compatible for straight insertion into all DERB destiny vectors. Should the ORF of interest not be 
commercially available, production of either a LoxP or Att donor vector is easily performed with a single PCR 
reaction with the Clontech in-fusion PCR cloning kit or Invitrogen attB-PCR cloning system, respectively. 
Production of all DERB expression vectors with recombinase based reactions abolishes the time constraint 
associated with ORF subcloning, restrictive enzyme digestion, DNA purification and ligation procedures. 
Efficiency in the DERB platform extends to enable the direct heat shock transformation of E. coli with 
recombination reaction mixtures in a multi-well format. This ability permits high throughput selection 
including ccdB replacement and antibiotic resistance acquirement enabling the generation of only clones 
containing the desired insert. The LR Clonase insertion of ORF1 into the Att loci of the DERB vector removes 
the ccdB construct from the resultant single expression vector and attaches it to the recombination byproduct 
to prevent its growth in E. coli DH5α (Fig. 1aii). Subsequent CRE mediated recombination introduces ORF2-
CmR into a DERB single expression vector forming a dual expressing vector, which renders its resistance to 
chloramphenicol and sucrose. The donor vector sensitivity to sucrose (SucB) and the single expression DERB 
vector deficient of CmR gene collectively prevent the proliferation of clones with unsuccessful recombination 
plasmids (Fig. 1aiii). The aforementioned selection strategy provides highly efficient dual expression vector 
generation with rare exceptions, thus rendering extensive clone selection from those generated as a redundant 
practice (See Supplementary: DERB Selection Strategy for details). That, coupled to the ability of 
immediate introduction into prokaryotic or eukaryotic cells, demonstrates the capability and efficiency of the 
platform for enabling high throughput formatting of protein interaction examination.  
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Translating the proteins of interest fused to either the ECFP EYFP or Yc Yn set of fluorescent tags provides a 
direct path for the FRET or BiFC detection of protein interactions. Expression of the ORF partners is 
controlled by the dual presence of an identical (pT7, CMV) or similar (modified FerH, FerL) promoter, which 
is responsible for the induction of both fusion proteins, and ensures their simultaneous expression at 
substantial levels (Fig. 5c). The well cited FRET donor-sensitized acceptor fluorescence three-channel 
method19,20 for the detection of protein interactions enables the use of numerous generic analyzers thus 
increasing the accessibility of the DERB technology. In the conformational experiments utilizing confocal 
microscopy, images of the controls and experimental groups were acquired with an identical laser intensity 
and PMT value. FRETN was obtained through the equation of Xia21,22 which provided measurements with a 
standard error of less than 7%19. Though confocal microscope analysis is reliable for FRETN measurement, it 
is difficult to be integrated into a high throughput protocol. As such, it is best to utilize confocal microscopy as 
a final confirmation to complement the limitations of the individual analyzers with the strengths of the 
alternatives.  Automation of the plate reader and/or flow cytometry BiFC analysis to determine protein 
interaction, however, is highly probable. The collection of EYFP fluorescence intensity and the determination 
of background threshold would enable immediate interaction detection. Introducing BiFC investigation into 
the multi-well plate reader and/or flow cytometry complements the time consuming limitations of confocal 
microscopy analysis and renders BiFC practice highly applicable to high throughput formatting. Furthermore, 
the scrutiny of quantifying channel cross-talk and ECFP-EYFP fluorescence equalization is removed, 
attracting greater efficiency to its detection. 
Companies including InVivogen and Novagen provide products used for the subcloning of two ORFs of 
interest into a single expression plasmid. Their technology mediates vector construction through the classical 
cloning methodology, which prevents formatting for high throughput screening. Gateway cloning platforms, 
offered by Invitrogen, introduced destiny vectors with recombination sites to facilitate recombinase insertion 
of multiple ORFs23. Despite its recombination advantage, Invitrogen destiny vectors do not innately encode a 
reporter fragment at the recombination loci and require the individual attachment of markers to donor vectors 
for protein interaction determination. Furthermore, aforementioned commercially available donor vector 
libraries compatible for direct insertion into Invitrogen cannot be used to detect interactions in the living cells. 
Regardless, the widely used single expression vectors with an ORF fused reporter fragment require co-
transfection, need selection of double transfected cells from the single transfected and non-transfected, 
questioning its efficiency. Complications extend to the unequal expression of proteins in the cells co-
transfected by single expression vectors as the ratio of different vectors integrated into individual cells cannot 
be controlled, which creates bias amongst the reporter tags, leading to pseudo-negative results. In contrast, the 
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DERB platform technology has been engineered with consideration to the shortfalls of the gateway cloning 
and hence mediates insertion into recombination sites with an in-frame fused reporter fragment through two 
recombinase-mediated reactions with commercially available donor vectors. High throughput transfection 
initiates the expression of both tagged proteins at similar levels, ensuring straightforward interaction detection 
which was validated by our proof-of-principle experiments.  
 
The platform’s unique ability to test a series of proteins in search of an interaction partner(s) with a known 
protein confirmed the interaction between ADIPOR1 and ADIPOR1. Western blotting confirmed the 
simultaneous expression of the Yn or Yc tagged ADIPOR1 proteins after the single transfection of living cells, 
establishing the interaction and reliability of the system. The adiponectin receptor signal transduction system 
is essential in many illnesses including diabetes, obesity and cancer, which are important public health issues. 
The interaction between adiponectin receptor 1 is likely significant to the activation and subsequent signal 
transduction as dimerization or polymerization of receptors is well known to be important for signaling 
functions24. Our platform provides a simple tool for the screening and verification of receptor interaction 
partners.  
A possible concern regarding the workability of the destiny vectors relates to their large size25. It has been 
reported that about 300kb of an insert sequence can be cloned or subcloned into common vectors26. The size 
of our destiny vectors without ORFs is approximately 7-8kbs, while the final dual expression vectors with two 
ORFs is extended to 11-13kb. There was no noticeable difficulty in the cloning and subcloning procedures 
with these vector clones. Strong signal of protein interaction in our system implied the expression and 
interaction of the tagged proteins were not obviously altered by the present size range of the plasmid vectors. 
 
In summary, the dual expression recombinase based (DERB) vector platform provides a technique for rapid, 
efficient and faultless cloning/subcloning of two ORFs in-frame with detection tags.  Resulting vectors can 
express both tagged proteins by a single transformation/transfection reaction. This system permits detection 
within 24hrs of transformation. Its selective culture strategy ensures that practically all the E. coli cells grown 
in the selective media express substantial amounts of two tagged proteins from the dual expression DERB 
vector, minimizing pseudo-negative output during screening. FRET or BiFC signal detection with a plate 
reader and/or a flow cytometer guarantees high specificity of the signal in prokaryotic and/or eukaryotic cells 
during screening and/or verification while providing the option of high throughput application. Thus, the 
DERB presents an alternative and unique method for the high throughput identification of protein interactions 
which overcomes the limitations associated with existing technologies (Supplementary Comparison of 
Technologies). While the present paper described only two detection methodologies (FRET, BIFC), we are 
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undertaking construction of new detection platforms including enzyme fragment complementation27 to broad 
the applications/capability of the DERB technology. The platform is further being used to screen for 
modulators of protein interactions by means of applying modulator candidates to the culture medium, an 
application not possible with current commercially available products or techniques. Given the interest of 
academic and commercial laboratories in the investigation of protein function and the development/screening 
of novel drugs, the DERB platform possesses universal appeal and tremendous financial value. 
 
 
METHODS 
DERB vector compilation. Commercially obtained plasmids pDNR, pLP-ECFP, pEYFP, pEYFP-Tub 
(Clontech) and pDEST, pT-Rex-DEST30, pRSET-A, pENTR221-ADIPOR1, pENTR221-ADIPOR2 
(Invitrogen) were directly applied to the creation and examination of the DERB platform. FRET destiny 
vectors comprised of the ECFP EYFP set of tags were introduced into prokaryotic (Supplementary Table 1) 
and eukaryotic (Supplementary Table 2) cells whereas BiFC destiny vectors with the Yc Yn tag set were 
introduced into eukaryotic cells (Supplementary Table 3). The sources of other entry vector or other vectors 
with the ORF of interest used are listed in Supplementary Table 4. 
 
Cell culture and transfection. E. coli DB3.1 (Invitrogen), and DH5α (New England Biolabs) served host for 
prokaryotic and eukaryotic DERB vector generation. E. coli BL21(DE3) expressed DERB vector proteins 
after induction with IPTG (1~2mM) for 6-16h at 18-25°C for interaction analysis. HeLa (ATCC, CCL-2) cells 
were grown in MEMα (Invitrogen) media supplemented with 10% FCS, 10U/ml penicillin, 100μg/ml 
streptomycin, non-essential amino acid and L-glutamine (Invitrogen). Mammalian cells were seeded onto 
glass cover slips in multi-well culture plates and transfected with DERB vectors through Lipofectamine-2000 
(Invitrogen), PEI (MBI, Fermentas) or CaPi (Promega) methods 24 h after seeding.  
 
Statistical analysis. Experimental data was subjected to a two-tailed paired sample t-test analysis.  Standard 
deviation (STDV) was calculated from at least three triplicates per experiment for the plate reader examination 
of FRETN and EYFP. Mock transfected HeLa and E. coli cells presented the zero expression level for the 
plate reader, flow cytometer, confocal microscope and fluorescent microscope. Supplementary controls, 
specific to the experiment, ensured reliability of the experimental group data and were only considered 
statistically significant if p values were less than 0.05. 
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Additional Methods. Description of the sample preparations for immunoprecipitation and western blot in 
addition to FRET and BiFC analysis with the confocal microscope, plate reader, flow cytometer and 
fluorescent microscope are presented in Supplementary Methods 2. Please refer to Supplementary 
Methods 3 for MIMX information (The minimum information required for reporting a molecular interaction 
experiment)28.  
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